Intracoronary bolus administration of eptifibatide during percutaneous coronary stenting for non ST elevation myocardial infarction and unstable angina

Journal of Thrombosis and Thrombolysis

Volumn 22, Issue 1, 2006, Pages 47-50

  Deibele, Albert J ^a   Kirtane, Ajay J ^b   Pinto, Duane S ^b   Lucca, Michael J ^a   Neva, Cathy ^a   Shui, Amy ^b   Murphy, Sabina A ^b   Tcheng, James E ^c   Gibson, C Michael ^b,d  

^a Duluth Clinic   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d NONE   (United States)

Author keywords

Glycoprotein IIb IIIa receptor inhibitor; Intracoronary; Non ST elevation myocardial infarction; Unstable angina

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; ENOXAPARIN; EPTIFIBATIDE; HEPARIN;

ADULT; AGED; ARTICLE; BOLUS INJECTION; CONTINUOUS INFUSION; CONTROLLED STUDY; CORE LABORATORY; CORONARY STENT; DOSE RESPONSE; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; DRUG WITHDRAWAL; FEASIBILITY STUDY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HEART MUSCLE PERFUSION; HUMAN; INTRACORONARY INFUSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; REVASCULARIZATION; UNSTABLE ANGINA PECTORIS;

AGED; ANGINA, UNSTABLE; ANGIOPLASTY, BALLOON; CORONARY ANGIOGRAPHY; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; REGIONAL BLOOD FLOW; RETROSPECTIVE STUDIES; STENTS; THROMBOEMBOLISM;

EID: 33745236055     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-006-7454-8     Document Type: Article

References (18)

1. Enhanced suppression of the platelet IIb/IIIareceptor with integrilin therapy (ESPRIT) investigators (2000) Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomized placebo controlled trial. Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy. Lancet 356:2037-2044
2. Integrilin to minimise platelet aggregation and coronary thrombosis-II (IMPACT II) investigators (1997) Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 349:1422-1428
3. Evaluation of platelet IIb/IIIa inhibitor for stenting (EPISTENT) investigators (1998) Randomized placebo controlled and balloon angioplasty controlled trial to assess safety of coronary stenting with use of glycoprotein IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 352:87-92
4. Evaluation in PTCA to improve long-term outcome with abciximab gp IIb/ IIIa blockade (EPILOG) investigators (1997) Platelet glycoprotein IIb/ IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 336:1689-1696
5. Moser M, Bertram U, Peter K, Bode C, Ruef J. (2003) Abciximab, Eptifibatide, Tirofiban Exhibit dose-dependent potencies to dissolve platelet aggregates. J Cardiovasc Pharmacol 41:586-592
6. Goto S, Tamura N, Ishida H (2004) Ability of anti-glycoprotein IIb/IIIa agents to dissolve platelet thrombi formed on a collagen surface under blood flow conditions. J Am Coll Cardiol 44:316-323
7. Gibson CM, Jennings LK, Murphy SA, et al (2004) Association between platelet receptor occupancy after eptifibatide (integrilin) therapy and patency, myocardial perfusion, and ST-segment resolution among patients with ST-segment-elevation myocardial infarction. an INTEGRITI (integrilin and tenecteplase in acute myocardial infarction) substudy. Circulation 110:679-684
8. Thrombolysis in Myocardial Infarction (TIMI) study group (1985) The thrombolysis in myocardial infarction (TIMI) trial. phase I findings. N Engl J Med 312:932-936
9. Gibson CM, Cannon CP, Daley WL, et al (1996) TIMI frame count: A quantitative method of assessing coronary artery flow. Circulation 93:879-888
10. Gibson CM, Cannon CP, Murphy SA, et al (2000) Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation 101:125-130
11. Gibson CM. (2004) A randomized trial to evaluate the relative protection against post-PCI microvascular dysfunction and post-PCI ischemia among anti-platelet and anti-thrombotic agents. New Orleans: Texas Heart Symposium.
12. Mitchel JF, Alberghini TV (1996) Site-specific thrombolysis with reopro. Circulation 94:I202
13. Mitchel JF, Alberghini TV (1996) Local delivery of reopro: pharmacokinetics and effect on platelet deposition following balloon angioplasty. Circulation 94:I202
14. Bailey SR, O'Leary E, Chilton R (1997) Angioscopic evaluation of site-specific administration of reopro. Catheter Cardiovasc Diagn 42:181-184
15. Bartorelli AL, Trabattoni D, Galli S, Grancini L, Cozzi S, Ravagnani P (1999) Successful dissolution of occlusive thrombus with local administration of abciximab during PTCA. Catheter Cardiovasc Interv 48:211-213
16. Wöhrle J, Grebe OC, Nusser T, et al (2003) Reduction of major adverse cardiac events with intracoronary compared with intravenous bolus application of abciximab in patients with acute myocardial infarction on unstable angina undergoing coronary angioplasty. Circulation 107:1840-1843
17. Kakkar AK, Moustapha A, Hanley HG, et al. (2004) Comparison of intracoronary vs intravenous administration of abciximab in coronary stenting. Catheter Cardiovasc Interv 61:31-34
18. Physicians' Desk Reference (2005). 59th Edition. Montvale, NJ, Medical Economics Company, pp. 2203-2207